Phase II Study, Randomized, Double-Blind, Placebo-Controlled 4-Week Clinical Study, to Evaluate the Efficacy and Safety of MK-7264 in Adult Japanese Participants With Unexplained or Refractory Chronic Cough
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Gefapixant (Primary)
- Indications Cough
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 21 Jun 2018 Status changed from active, no longer recruiting to completed.
- 09 May 2018 Planned End Date changed from 9 Jul 2018 to 7 Jun 2018.
- 09 May 2018 Planned primary completion date changed from 9 Jul 2018 to 7 Jun 2018.